Air India CEO Meets Regulators After Pilot Fails Dope Test

Air India's Chief Executive Officer met with officials from the Directorate General of Civil Aviation (DGCA) and the Ministry of Civil Aviation (MoCA) on Monday. The meeting was prompted by a severe turbulence event involving a Phuket-Delhi flight that experienced a sudden 300-foot altitude drop. This incident has been classified by experts as a rare flight-control event, raising serious questions about operational safety protocols. Regulators are demanding a comprehensive explanation of the technical failures that led to the altitude loss. The discussions focused on ensuring such technical or human-led errors do not recur in future operations.

Compounding the technical investigation is a controversial development involving the flight's pilot, who reportedly failed a second drug test. According to internal sources, the pilot tested positive for prohibited substances, though the specific chemicals have not been publicly disclosed. There is ongoing debate within the airline and regulatory circles regarding the accuracy of these results. Some experts suggest that certain common medications could trigger false-positive readings in standard dope tests. The DGCA has issued an advisory to pilots regarding the consumption of common drugs that might interfere with mandatory screening processes.

The fallout from these twin incidents has placed Air India under intense public and regulatory pressure. The airline is expected to tighten its pre-flight and post-flight medical screening procedures for all cockpit crew members. For the Indian aviation sector, this case highlights the critical need for modernized drug testing technologies that can distinguish between therapeutic medication and recreational drug use. A final report from the DGCA is anticipated within the next few weeks, which will determine if any punitive actions or license suspensions will be imposed. Air India has vowed full cooperation with the ongoing probe to maintain its safety standards.